The activity of 8-iso-prostaglandin F2α as an oxidative stress marker In Vivo in paediatric patients with type 1 diabetes mellitus and associated autoimmunities

Clinical Laboratory

Volumn 60, Issue 2, 2014, Pages 253-259

  Rǎchişan, Andreea Liana ^a   Hruşcǎ, Adrian ^a   Cǎinap, Simona ^a   Pop, Tudor Lucian ^a   Andreica, Mariana ^a   Miu, Nicolae ^a   Samaşca, Gabriel ^a  

^a IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

Children; Diabetes mellitus type 1; Oxidative stress

Indexed keywords

8 ISOPROSTAGLANDIN F2 ALPHA; GLUTAMATE DECARBOXYLASE 65; HEMOGLOBIN A1C; INSULIN;

ADOLESCENT; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CHILD; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IN VIVO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; SCHOOL CHILD;

ADOLESCENT; AUTOIMMUNITY; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHILD; DIABETES MELLITUS, TYPE 1; DINOPROST; FEMALE; GLUTAMATE DECARBOXYLASE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; OXIDATIVE STRESS;

EID: 84895806991     PISSN: 14336510     EISSN: None     Source Type: Journal    
DOI: 10.7754/Clin.Lab.2013.121141     Document Type: Article

References (22)

1. Kaviarasan S, Muniandyl S, Qvist R, Chinna K, Ismail IH. Is F2-isoprostane a biological marker for the early onset of type 2 diabetes mellitus? Int J Diab Dev Ctries 2010;30:167-70.
2. Pratico D. F2-isoprostanes: Sensitivity and specific non-invasive indices of lipid peroxidation in vivo. Atherosclerosis 1999;147:1-10. (Pubitemid 29486766)
3. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-12.
4. Ceriello A, Hanefeld M, Leiter L, et al. Postprandial glucose regulation and diabetic complications. Arch Intern Med 2004;164: 2090-5. (Pubitemid 39410797)
5. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001;414:813-20. (Pubitemid 34000785)
6. Turk Z. Glycotoxines, carbonyl stress and relevance to diabetes and its complications. Physiol Res Jun 19 (2009).
7. Wu LL, Chiou CC, Chang PY, Wu JT. Urinary 8-OHdG: a marker of oxidative stress to DNA and a risk factor for cancer, atherosclerosis and diabetics. Clin Chim Acta 2004;339:1-9. (Pubitemid 37542453)
8. Dong QY, Cui Y, Chen L, Song J, Sun L. Urinary 8-hydroxydeoxyguanosine levels in diabetic retinopathy patients. Eur J Ophthalmol 2008;18:94-8. (Pubitemid 351428556)
9. West I. Radicals and oxidative stress in diabetes. Diabet Med 2000;17:171-80. (Pubitemid 30212288)
10. Davi G, Chiarelli F, Santilli F, et al. Enhanced lipid peroxidation and platelet activation in the early phase of type 1 diabetes mellitus. Role of interleukin-6 and disease duration. Circulation 2003; 107:3199-203. (Pubitemid 36793091)
11. Flores L, Rodela S, Abian J, Claria J, Esmatjes E. F2 isoprostane is already increased at the onset of type 1 diabetes mellitus: effect of glycemic control. Metabolism 2004;9:1118-20. (Pubitemid 39140743)
12. Basu S. F2-isoprostanes in human health and diseases: from molecular mechanism to clinical implications. Antioxidants and Redox Signaling 2008;10:1405-33.
13. Eisenbarth GS. Type I diabetes mellitus. A chronic autoimmune disease. The New England Journal of Medicine 1986;314(21): 1360-8. (Pubitemid 16122469)
14. Lander HM, Tauras JM, Ogiste JS, et al. Activation of the receptor for advanced glycation end-products triggers a p21(ras) dependent mitogen activated protein kinase pathway regulated by oxidant stress. J Biol Chem 1997;272:17810-4. (Pubitemid 27311222)
15. Ceriello A, Quagliaro L, Piconi L, et al. Effect of postprandial hypertriglyceridemia and hyperglycemia on circulating adhesion molecules and oxidative stress generation and the possible role of simvastatin treatment. Diabetes 2004;53:701-10. (Pubitemid 38270640)
16. Bach JF. Insulin-dependent diabetes mellitus as an autoimmune disease. Endocrine Reviews 1994;15(4):516-42.
17. American Diabetes Association: Diagnosis and classification of diabetes mellitus. Diabetes Care 2005;28 (Suppl. 1):S37-S42.
18. Winter WE, Harris N, Schatz DA. Type 1 diabetes islet autoantibodies markers. DiabetesTechnol Ther 2002;4:817-39. (Pubitemid 36172465)
19. Kawasaki E, Takino H, Yano M, et al. Autoantibodies to glutamic acid decarboxylase in patients with IDDM and autoimmune thyroid disease. Diabetes 1994;43:80-6.
20. Graham J, Hagopian WA, Kockum I, et al. Genetic effects on age-dependent onset and islet cell autoantibody markers in type 1 diabetes. Diabetes 2002;51:1346-55. (Pubitemid 34826598)
21. Kimpimaki T, Kupila A, Hamalainen AM, et al. The first signs of beta-cell autoimmunity appear in infancy in genetically susceptible children from the general population: the Finnish Type 1 Diabetes Prediction and Prevention Study. J Clin Endocrinol Metab 2001;86:4782-8. (Pubitemid 33020520)
22. Kanatsuna N, Papadopoulos GK, Moustakas AK, Lenmark A. Etiopathogenesis of Insulin Autoimmunity. Anatomy Research International 2012, doi:10.1155/2012/457546.